Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder

Eller, Triin; Vasar, Veiko; Shlik, Jakov; Maron, Eduard

doi:10.1016/j.pnpbp.2007.09.015

Cited by 274 publications

(191 citation statements)

References 36 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…An investigation on patients with rapid-cycling bipolar disorder also showed that obesity was associated with a poorer treatment response to lithium and valproate (Kemp et al, 2010). Inflammation and increased pro-inflammatory cytokine production, commonly observed in obesity, are also associated with a poor antidepressant treatment response (Eller et al, 2008, O'Brien et al, 2007, Yoshimura et al, 2009. No studies have been identified investigating the effect of obesity on psychological and other non-drug treatments for psychiatric disorders.…”

Section: What Effect Does Obesity Have On Treatment Outcomes?mentioning

confidence: 99%

Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment

Lopresti

Drummond

2013

Progress in Neuro-Psychopharmacology and Biological Psychiatry

193

128

View full text Add to dashboard Cite

Rates of obesity are higher than normal across a range of psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia and anxiety disorders. While the problem of obesity is generally acknowledged in mental health research and treatment, an understanding of their bi-directional relationship is still developing. In this review the association between obesity and psychiatric disorders is summarised, with a specific emphasis on similarities in their disturbed biological pathways; namely neurotransmitter imbalances, hypothalamus-pituitary-adrenal axis disturbances, dysregulated inflammatory pathways, increased oxidative and nitrosative stress, mitochondrial disturbances, and neuroprogression. The applicability and effectiveness of weight-loss interventions in psychiatric populations is reviewed along with their potential efficacy in ameliorating disturbed biological pathways, particularly those mediating inflammation and oxidative stress. It is proposed that weight loss may not only be an effective intervention to enhance physical health but may also improve mental health outcomes and slow the rate of neuroprogressive disturbances in psychiatric disorders. Areas of future research to help expand our understanding of the relationship between obesity and psychiatric disorders are also outlined.

show abstract

Section: What Effect Does Obesity Have On Treatment Outcomes?mentioning

confidence: 99%

Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment

Lopresti

Drummond

2013

Progress in Neuro-Psychopharmacology and Biological Psychiatry

193

128

View full text Add to dashboard Cite

show abstract

“…In recent decades, the crosstalk between the innate and adaptive immune systems and the brain has been suggested to represent a key factor in antidepressant drug action (Carvalho et al, 2013;Eller et al, 2008;Lanquillon et al, 2000;Tuglu et al, 2003). Indeed, treatment with SSRIs has been shown to decrease MD associated cytokine elevations.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, elevated baseline levels of TNFα and IL-6 correlate with treatment failure (Carvalho et al, 2013;Eller et al, 2008;Lanquillon et al, 2000). However, other clinical studies obtained opposite results, demonstrating no or even pro-inflammatory effects of antidepressant treatment (Chen et al, 2010;Haastrup et al, 2012;Hannestad et al, 2011;Jazayeri et al, 2010;Kim et al, 2013;Song et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Fluoxetine treatment affects the inflammatory response and microglial function according to the quality of the living environment

Alboni

Poggini

Garofalo

et al. 2016

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

It has been hypothesized that selective serotonin reuptake inhibitors (SSRIs), the most common treatment for major depression, affect mood through changes in immune function. However, the effects of SSRIs on inflammatory response are contradictory since these act either as anti-or pro-inflammatory drugs. Previous experimental and clinical studies showed that the quality of the living environment moderates the outcome of antidepressant treatment. Therefore, we hypothesized that the interplay between SSRIs and the environment may, at least partially, explain the apparent incongruence regarding the effects of SSRI treatment on the inflammatory response. In order to investigate such interplay, we exposed C57BL/6 mice to chronic stress to induce a depression-like phenotype and, subsequently, to fluoxetine treatment or vehicle (21days) while being exposed to either an enriched or a stressful condition. At the end of treatment, we measured the expression levels of several anti-and pro-inflammatory cytokines and inflammatory mediators in the whole hippocampus and in isolated microglia. We also determined microglial density, distribution, and morphology to investigate their surveillance state. Results show that the effects of fluoxetine treatment on inflammation and microglial function, as compared to vehicle, were dependent on the quality of the living environment. In particular, fluoxetine administered in the enriched condition increased the expression of pro-inflammatory markers compared to vehicle, while treatment in a stressful condition produced anti-inflammatory effects. These findings provide new insights regarding the effects of SSRIs on inflammation, which may be crucial to devise pharmacological strategies aimed at enhancing antidepressant efficacy by means of controlling environmental conditions. AbstractIt has been hypothesized that selective serotonin reuptake inhibitors (SSRIs), the most common treatment for major depression, affect mood through changes in immune function. However, the effects of SSRIs on inflammatory response are contradictory since these drugs act either as anti-or proinflammatory. Previous experimental and clinical studies showed that the quality of the living environment moderates the outcome of antidepressant treatment. Therefore, we hypothesized that the interplay between SSRIs and environment may, at least partially, explain the apparent incongruence regarding the effects of SSRI treatment on the inflammatory response. In order to investigate such interplay, we exposed C57BL/6 mice to chronic stress to induce a depression-like phenotype and, subsequently, to fluoxetine treatment or vehicle (21 days) while being exposed to either an enriched or a stressful condition. At the end of treatment, we measured the expression levels of several anti-and pro-inflammatory cytokines and inflammatory mediators in the whole hippocampus and in isolated microglia. We also determined microglial density, distribution, and morphology to investigate their surveillance state. Results show that...

show abstract

“…В настоящее время четко прослеживается тен-денция к выделению определенных подтипов де-прессии, имеющих патофизиологические особен-ности и характеризующиеся определенной чувстви-тельностью к различным терапевтическим воздей-ствиям [37][38][39][40][41]. Этот факт не может игнорироваться в разработке модели ТРД, иначе не исключено ее ошибочное расширение за счет псевдорезистентно-сти.…”

Section: модель Msmunclassified

Spectral model of therapy resistant depression

Мазо

Незнанов

Krizhanovsky

2015

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Более 40 лет проблема терапевтической рези-стентности при эндогенной депрессии остается од-ной из наиболее актуальных в клинической психиат-рии. Термин «терапевтически резистентная депрес-сия» (ТРД) уже давно вошел в повседневную прак-тику психиатров по всему миру. Однако данный термин по-разному трактуется специалистами. Еди-ным для всех врачей остается лишь понимание труд-ной курабельности состояния и сопереживание конкретному пациенту, которому не удается по-мочь.Одни исследователи [1] считают, что нечувстви-тельны к терапии около 15% пациентов, страдаю-щих депрессивным расстройством, другие [2] свиде-тельствуют о том, что не достигают полной редук-ции депрессивной симптоматики в течение антиде-прессивной терапии до 60% пациентов. В исследо-вании STAR*D [3] только 67% больных достигли ремиссии после 4 курсов терапии антидепрессанта-ми в течение 14 мес. Столь большой разброс в пока-зателях связан с отсутствием в литературе единого определения ТРД.В начальном периоде (1973)(1974)(1975)(1976)(1977)(1978)(1979)(1980)(1981)(1982)(1983) Ключевые слова: депрессия, терапевтическая резистентность, модели оценки.In the present article, we describe different staging models of therapy resistant depression (TRD). Their advantages and disadvantages are pointed out. Also the possibilities of using various TRD staging models in clinical practice are considered. It is proposed to develop a single spectral model of TRD. Key words: depression, treatment resistance, assessment models.чия в определениях ТРД затрудняют оценку ее рас-пространенности в популяции [6] и в известной ме-ре снижают возможность разработки эффективных терапевтических подходов к ее коррекции.Европейское агентство по лекарственным сред-ствам (EMEA) [7] предприняло попытку унифици-ровать определение ТРД, предложив следующее: «клинически значимой ТРД является текущий эпи-зод депрессивного расстройства, при котором по меньшей мере два адекватных курса антидепрессан-тов с разными механизмами действия не принесли успеха». Именно оно в настоящее время использует-ся в большинстве клинических исследований, на-правленных на преодоление резистентности. Одна-ко предложенное определение не позволяет класси-фицировать пациентов в соответствии с уровнем резистентности и соответственно прогнозировать их шансы на возможное наступление ремиссии. Для научных исследований и практической врачебной деятельности требуется лучшее понимание прогно-зирования течения и исхода заболевания и в этом отношении более целесообразны оценочные моде-ли, учитывающие стадийность заболевания. Одной из первых попыток выделения стадий терапевтиче-ской резистентности можно считать разделение ТРД на относительную и абсолютную [8].

show abstract

Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder

Cited by 274 publications

References 36 publications

Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment

Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment

Fluoxetine treatment affects the inflammatory response and microglial function according to the quality of the living environment

Spectral model of therapy resistant depression

Contact Info

Product

Resources

About